Imatinib

Japanese Journal of Clinical Immunology

Volumn 32, Issue 2, 2009, Pages 77-84

  Kameda, Hideto ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Fibroblast; Interstitial lung disease; Platelet derived growth factor; Systemic sclerosis

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTHRITIS; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; FIBROBLAST; GLOMERULONEPHRITIS; HUMAN; INTERSTITIAL PNEUMONIA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

ANIMALS; HUMANS; LUNG DISEASES, INTERSTITIAL; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 77953658589     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.32.77     Document Type: Review

References (44)

1. Peng B, Lloyd P, Schran H.: Clinical pharmacokinetics of imatinib: Clin Pharmacokinet 44: 879-894, 2005.
2. Carroll M, Ohno-Jones S, Tamura S, et al.: CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997.
3. Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
4. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and - safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
5. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCW-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
6. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
7. Varga J, Abraham D.: Systemic sclerosis: a prototypic multisystern fibrotic disorder. J Clin Invest 117: 557-567, 2009.
8. Daniels CE, Wikes MC, Edens M, et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316, 2004.
9. Pannu J, Asano Y, Nakerakanti S, et al.: Smadl pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58: 2528-25 37, 2008.
10. Heldin C-H, Westermark B, Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
11. Östman A, Heldin C-H, Involvement of platelet-defived growth-factor in- disease: development of specific antagonists. Adv Cancer Res 80: 1-38, 2001.
12. Pietras K, Sjöblom T, Rubin K, et al.: PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443, 2003.
13. Cheon H, Sun YKI Yu SJ, et al.: Platelet-derived growth. factor-AA increases IL-1β and IL-8 expression and activates NF-κB in rheumatoid fibroblast-like synoviocytes. Scand J Immmunol 60: 455-462, 2004.
14. Dietz AB, Souan L, Knutson GJ, et al.: Imatinib mesylate inhibits T-cell proliferation in vitro and ddlayed-type hypersensitivity in vivo. Blood 104: 1094-1099, 2004.
15. Cwynarski K, Laylor R, Macchiarulo E, et al.: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18: 1332-1339, 2004.
16. Seggewiss R, Loré K, Greiner E, et al.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation an d activation in a dose-dependent manner. Blood 105: 2473-2479, 2005.
17. Bachmann MF, Gallimore A, Linkert S, et al.: Developmental regulation of Ick targeting to the CD8 coreceptor controls signaling in naïve and memory T cells. J Exp J Med 189: 15217-1529, 1999.
18. Mumprecht S, Matter M, Pavelic V, et al.: Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108: 3406-3413, 2006.
19. Gu JJ, Zhang N, He Y-W, et al.: Defective T cell development and function in the absence of abelson kinases. J Immunol 179: 7334-7343, 2007.
20. Chen J, Schmitt A, Giannopoulos K, et al.: Imatinib impairs the proliferation and function of CD4 + CD25 + regulatory T c4s in a dose-dependent manner. Int J Oncol 31: k133-1139, 2007.
21. Borg C, Terme M, Taïeb J, et al.: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388, 2004.
22. Kameda H, Ishigami H, Suzuki M, et al.:Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin, Exp Immunol 144: 335-341, 2006.
23. Kimeda H, Suzuki M, Ishigami H, et al.: The proliferation of synovial fibroblast-like cells enhanced by platelet-derived growth factor is reversed by imatinib via cytoskeletal actin reorganization in 3-dimensional culture system (submitted).
24. Distler JHW, Jüngel A, Huber LG, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56: 311-322, 2007.
25. van Daele PLA, Dik WA, Thio HB, et al.: Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58: 2549-2552, 2008.
26. Japanese source.
27. Kameda H, Suzuki M, Takeuchi T.: Plateletderived growth factor as a therapeutic target for systemic autoimmune diseases. Drug Target Insights 2: 239-247, 2007.
28. Ando W, Hashimoto J, Nampei A, et al.: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24: 274-282, 2006.
29. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116: 2633-2642, 2006.
30. Koyama K, Hatsushika, K, Ando T, et al.: Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 17: 306-310, 2007.
31. Miyachi K, Ihara A, Hankins RW, et al.: Efficacy of imatinib mesylate (ST1571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 22: 329, 2003.
32. Eklund KK, Joensuu H.: Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 35: 362-367, 2003.
33. Abdollahi A, Li M, Ping G, et al.: Inhibition of platelet-derived growth factor signaling attenuate pulmonary fibrosis. J Exp Med 201: 925-935, 2005.
34. Aono Y, Nishioka Y, Inayama M, et al.: Imatinib as a novel antifibrotic agent in bleomycininduced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171: 1279-1285, 2005.
35. Chaudhary NI, Schnapp A, Park JE.: Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 173: 769-776, 2006.
36. Azuma M, Nishioka Y, Aono Y, et al.: Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176: 1243-1250, 2007.
37. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllärniemi M.: Imatinib mesylate inhibits fibrosis in asbestos-induced interstitial pneumonia. Exp Lung Res 33: 357-373, 2007.
38. Ohba T, Takase Y, Ohhara M, et al.: Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet-derived growth factor. J Rheumatol 23: 1505-1511, 1996.
39. Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354: 2667-2676, 2006.
40. Akhmetshina A, Venalis P, Dees C, et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 60: 219-224, 2009.
41. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM.: Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 47: 737-738, 2008.
42. Distler JHW, Manger B, Spriewald BM, Schett G, Distler O.: Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 59: 2538-2542, 2008.
43. Kay J, High WA.: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58: 2543-2548, 2008.
44. Spiera RF, Gordon JK, Mehta M, et al.: Phase II trial of imitinib mesylate (Gleevec) in the treatment of diffuse systemic sclerosis - An interim analysis. Arthritis Rheum 58 (Suppl): S623, 2008.